Botox safe, efficacious for crow’s feet lines

July 27, 2016 / Allergan, Botox, Brilliant Distinctions, neuromodulators

Botox safe, efficacious for crow’s feet lines

Results from two phase 3 clinical trials indicate that Botox can be used to treat crow’s feet lines safely and effectively, and researchers noted that two injection patterns are possible to customize treatment based on a patient’s crow’s feet lines pattern.


Alastair Carruthers, FRCPC, from Carruthers Clinical Research in Vancouver, British Columbia, Canada, and colleagues analyzed 1,362 patients with crow’s feet lines in two phase 3 studies who were treated with a 24 U dose of Botox (onabotulinumtoxinA, Allergan) or placebo. After evaluating 100 patients, they classified crow’s feet lines into four different patterns: full fan, lower fan, central fan, and upper fan.

Alastair Carruthers

Alastair Carruthers

The researchers used two different injection patterns that included three injections of onabotulinumtoxinA per side, depending on the crow’s feet lines pattern.

The researchers graded crow’s feet lines severity and efficacy of treatment using the Facial Wrinkle Scale and a photonumeric guide. At 30 days, patients who received onabotulinumtoxinA had a significantly higher responder rate compared with patients who received placebo (P < 0.001). Overall, full fan, central fan and lower fan crow’s feet lines comprised 90% of cases, and upper fan comprised 10% of cases. The only adverse event was eyelid edema, which was reported in 1% of patients who received onabotulinumtoxinA.

“The approval of onabotulinumtoxinA at the 24 U dose based on the phase 3 clinical trials provides a well-founded framework for clinical use,” Carruthers and colleagues wrote. “The presence of different [crow’s feet lines] patterns suggests that it may be possible to customize treatment administration with the 24 U dose based on the patient’s [crow’s feet lines] pattern.” – by Jeff Craven

BD logo

Disclosure: Carruthers is a consultant for and has received research grants from Allergan plc. Please see the full study for a complete list of other researchers’ relative financial disclosures.

Reposted from: Healio